The FDA has approved an expanded label for GlaxoSmithKline’s new Trelegy Ellipta inhaler, allowing it to be used in a broader population of patients with chronic obstructive pulmonary disease ...

AstraZeneca’s Symbicort inhaler accounts for most of its inhalation ... Meanwhile GSK's lead inhalers include Trelegy Ellipta, projected to bring $3.3bn in 2024 sales, followed by Relvar/Breo ...